Most Read Articles
Rachel Soon, 5 days ago

On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.

Jackey Suen, 08 Oct 2018

Adding pertuzumab to trastuzumab plus an aromatase inhibitor (AI) improves progression-free survival (PFS) in patients with HER2-positive metastatic or locally advanced breast cancer, the phase II PERTAIN study has shown.

05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Laura Kho Sui San , 29 May 2019
Anxiety becomes a pathological disorder when it occurs for no detectable reason, persists and interferes with daily activities like work performance and relationships.

Alirocumab yields mortality benefits in acute coronary syndrome

04 Jun 2019

The addition of alirocumab to intensive statin therapy appears to cut the risk of death following acute coronary syndrome (ACS), especially if treatment is sustained for at least 3 years, if baseline low-density lipoprotein cholesterol (LDL-C) is ≥100 mg/dL or if achieved LDL-C is low, according to data from the ODYSSEY OUTCOMES.

The trial randomized 18,924 patients, who had an ACS 1–12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy, to receive either alirocumab or placebo. Treatment dose was blindly titrated to achieve LDL-C targets (25–50 mg/dL). Outcomes of interest were all-cause death and its components, cardiovascular and noncardiovascular death.

Over a median follow-up of 2.8 years, 334 patients (3.5 percent) in the alirocumab group and 392 (4.1 percent) in the placebo group died (hazard ratio [HR], 0.85, 95 percent CI, 0.73–0.98; p=0.03). This survival advantage with the study drug was attributed to nonsignificantly fewer cardiovascular (2.5 percent vs 2.9 percent; HR, 0.88, 0.74–1.05; p=0.15) and noncardiovascular deaths (1.0 percent vs 1.3 percent; HR, 0.77, 0.59–1.01; p=0.06).

In the group of 8,242 patients who completed ≥3 years of follow-up, alirocumab conferred significant protection against death (HR, 0.78, 0.65–0.94; p=0.01). Of note, patients with nonfatal cardiovascular events were at increased risk of cardiovascular and noncardiovascular deaths (p<0.0001), but treatment with alirocumab led to a lower incidence of total nonfatal cardiovascular events (p<0.001) and might have thus attenuated the number of noncardiovascular deaths.

Posthoc analysis revealed that patients with baseline LDL-C ≥100 mg/dL had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71, 0.56–0.90; p-interaction=0.007) compared with those who had lower LDL-C. The risk of all-cause death decreased in alirocumab-treated patients who achieved LDL-C target (approximately 30 mg/dL) at 4 months of treatment (p-trend=0.017).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 5 days ago

On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.

Jackey Suen, 08 Oct 2018

Adding pertuzumab to trastuzumab plus an aromatase inhibitor (AI) improves progression-free survival (PFS) in patients with HER2-positive metastatic or locally advanced breast cancer, the phase II PERTAIN study has shown.

05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Laura Kho Sui San , 29 May 2019
Anxiety becomes a pathological disorder when it occurs for no detectable reason, persists and interferes with daily activities like work performance and relationships.